XOMA Corporation

Equities

XOMA

US98419J2069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
24.78 ^USD	-2.59%		-2.48%	+33.95%

Apr. 30	XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	CI
Apr. 29	Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	MT

XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022

May 05, 2022 at 07:54 am EDT

XOMA Corporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 3.11 million compared to USD 0.375 million a year ago. Net loss was USD 2.28 million compared to USD 7.37 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.7 a year ago.

Latest news about XOMA Corporation

XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	Apr. 29	CI
Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	Apr. 29	MT
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	Apr. 02	CI
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
XOMA Agrees to Acquire Kinnate Biopharma	Feb. 16	MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	Feb. 15	CI
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	Jan. 18	MT
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	Jan. 17	CI
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment	Jan. 12	MT
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	Jan. 11	DJ
Xoma Names Owen Hughes as Chief Executive Officer	Jan. 08	CI
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	Jan. 08	CI
XOMA Authorizes $50 Million Share Buyback Program	Jan. 02	MT
XOMA Authorizes $50 Million Share Buyback Program	Jan. 02	MT
XOMA Corporation announces an Equity Buyback for $50 million worth of its shares.	Jan. 02	CI
XOMA Corporation authorizes a Buyback Plan.	Jan. 01	CI
Sector Update: Health Care Stocks Gain in Afternoon Trading	Dec. 19	MT
Xoma Gets Up To $140 Million Royalty-Backed Loan From Blue Owl Capital; Xoma Shares Rise	Dec. 19	MT
Xoma-Non-Dilutive, Non-Recourse, Royalty-Backed Loan For Up To $140 Million Of Capital	Dec. 19	RE
XOMA Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (XOMA) XOMA CORPORATION Reports Q3 Revenue $830,000	Nov. 07	MT
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31	MT
ObsEva to Return Global Rights on Ebopiprant to Xoma	23-10-30	MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating	23-08-09	MT

Chart XOMA Corporation

Duration

Period

More charts

Company Profile

XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for XOMA Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

24.78 USD

Average target price

57 USD

Spread / Average Target

+130.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XOMA CORPORATION	+33.95%	288M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B

Bio Therapeutic Drugs